KHB(SZ:002022) Sou Hu Cai Jing·2025-05-12 08:44Company Overview - Kewah Bioengineering Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents and medical testing instruments [1] - The company's main products include biochemical diagnostics, immunodiagnostics, biochemical immunodiagnostic automation, molecular diagnostics, mass spectrometry, POCT (colloidal gold), and agency services [1] - Kewah has received several honors, including the National Science and Technology Progress Award, recognition as a National High-tech Enterprise, and being a pilot enterprise for national intellectual property [1] Financial Performance - For Q1 2025, Kewah reported revenue of 388 million yuan, a year-on-year decrease of 12.50% [1] - The net profit for the same period was -53.26 million yuan, reflecting a year-on-year decline of 84.79% [1] - The company's gross profit margin stood at 37.39% [1] Market Position - As of the latest data, Kewah's stock closed at 6.09 yuan, down 4.25%, with a price-to-book ratio of 0.96 and a total market capitalization of 3.132 billion yuan [1] - Five institutions hold shares in Kewah, with a total of 114.66 million shares valued at 649 million yuan [1] Industry Comparison - Kewah's PE (TTM) is -4.71, while the industry average is 49.84 [2] - The industry median PE is 36.59, indicating Kewah's significant underperformance compared to peers [2] - The total market capitalization of Kewah is 3.132 billion yuan, which is lower than several competitors in the industry [2]